GnRH‐a + estriol vs GnRH‐a ± placeboBone density (SMD) ‐ · patients with uterine fibroids1 finding from 1 reviewAdd‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 12 participantsLow
GnRH‐a + tibolone vs GnRH‐a ± placeboBone density (SMD) ‐ · patients with uterine fibroids1 finding from 1 reviewAdd‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes onlyno estimate extracted3 studies · 160 participantsModerate
GnRH‐a + raloxifene vs GnRH‐a ± placeboBone density (SMD) ‐ · patients with uterine fibroids1 finding from 1 reviewAdd‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 91 participantsLow
GnRH‐a + ipriflavone vs GnRH‐a ± placeboBone density (SMD) ‐ · patients with uterine fibroids1 finding from 1 reviewAdd‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 95 participantsLow
GnRH‐a + medroxyprogesterone acetate vs GnRH‐a ± placeboBone density (SMD) ‐ · patients with uterine fibroids1 finding from 1 reviewAdd‐back therapy with GnRH analogues for uterine fibroids 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 16 participantsLow